The Safety of Continuing Low-dose Aspirin Therapy Perioperatively in the Patients had Undergone Percutaneous Nephrolithotomy: A Systematic Review and Meta-analysis A Review of continuing aspirin during PCNL
Vol. 19 No. 04 (2022),
Purpose: Aspirin (ASA) is often stopped prior to percutaneous nephrolithotomy (PCNL) due to the surgical bleeding risk. However, this practice is based on expert opinion only, and mounting evidence suggests holding aspirin perioperatively can be more harmful than once thought. In our review we aimed to discuss the safety of low dose aspirin continued or discontinued in the whole perioperative period of PCNL.
Patients and Method: We performed a computerized PubMed, EMBASE and Cochrane Library search of relevant studies. Study identification satisfied the PRISMA guidelines. Newcastle-Ottawa scale (NOS) was used to evaluate the quality of including studies. Favored outcomes such as operative time, complications and change in hemoglobin were extracted. Statistical analysis was performed with Rev-Man software 5.3 and forest plots were used to illustrate our findings.
Results: After screening, four studies were included in the present systematic review. There was no difference in the number of total complications (OR:1.25; 95 % CI 0.82-1.90; p=0.30), major complications (OR: 1.24; 95 % CI 0.53-2.93; p=0.62) and blood transfusion rate (OR:0.99; 95 % CI 0.46-2.12; p=0.98) between the continuing low dose aspirin group and discontinuing group. Moreover, the overall stone-free rate was also not statistically significant (OR:3.17; 95 % CI 0.89-11.25; p=0.07). It was similar about the change in hemoglobin, hematocrit and creatinine levels between two groups.
Conclusion: Based on our findings, transient cessation of aspirin perioperatively seems not to be necessary for patients who need PCNL complicated with the necessity of aspirin therapy. However, further well-designed prospective studies with large sample size are needed to confirm and validate our findings.
- Percutaneous Nephrolithotomy
How to Cite
Türk C, Petřík A, Sarica K, Seitz C, Skolarikos A, Straub M, et al. EAU Guidelines on Interventional Treatment for Urolithiasis. Eur Urol. 2016;69:475-82.
Barone B, Crocetto F, Vitale R, Di Domenico D, Caputo V, Romano F, et al. Retrograde intra renal surgery versus percutaneous nephrolithotomy for renal stones >2 cm. A systematic review and meta-analysis. Minerva Urol Nefrol. 2020;72:441-50.
Lai D, He Y, Li X, Chen M, Zeng X. RIRS with Vacuum-Assisted Ureteral Access Sheath versus MPCNL for the Treatment of 2-4 cm Renal Stone. Biomed Res Int. 2020;2020:8052013.
Labate G, Modi P, Timoney A, Cormio L, Zhang X, Louie M, et al. The percutaneous nephrolithotomy global study: classification of complications. J Endourol. 2011;25:1275-80.
Keoghane SR, Cetti RJ, Rogers AE, Walmsley BH. Blood transfusion, embolisation and nephrectomy after percutaneous nephrolithotomy (PCNL). BJU Int. 2013;111:628-32.
Otto B, Lutfi F, Gupta M, Terry R, Bird VG. The effect of continued aspirin therapy in patients undergoing PCNL. Journal of Endourology. 2016;30:A370-A1.
Tran T, Parkhomenko E, Thai J, Blum K, Gupta M. Continuing aspirin does not increase blood loss from percutaneous nephrolithotomy. Journal of Urology. 2017;197:e921.
Siev M, Motamedinia P, Leavitt DA, Keheila M, Kiewe R, Okeke Z. Safety of percutaneous nephrolithotomy in patients on antithrombotic therapy: a review of guidelines and recommendations. Minerva Urol Nefrol. 2015;67:303-15.
Vaclavik J, Taborsky M. Antiplatelet therapy in the perioperative period. Eur J Intern Med. 2011;22:26-31.
Kiberd MB, Hall RI. Aspirin in the perioperative period: a review of the recent literature. Curr Opin Anaesthesiol. 2015;28:349-55.
Gerstein NS, Schulman PM, Gerstein WH, Petersen TR, Tawil I. Should more patients continue aspirin therapy perioperatively?: clinical impact of aspirin withdrawal syndrome. Ann Surg. 2012;255:811-9.
Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. Bmj. 2015;350:g7647.
Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. Bmj. 2019;366:l4898.
Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. Bmj. 2016;355:i4919.
Jolliffe D, Murray J, Farrington D, Vannick C. Testing the Cambridge quality checklists on a review of disrupted families and crime. Crim Behav Ment Health. 2012;22:303-14.
Falahatkar S, Esmaeili S, Rastjou Herfeh N, Kazemnezhad E, Falahatkar R, Yeganeh M, et al. The safety of continued low dose aspirin therapy during Complete Supine Percutaneous Nephrolithotomy (csPCNL). Prog Urol. 2021.
Leavitt DA, Theckumparampil N, Moreira DM, Elsamra SE, Waingankar N, Hoenig DM, et al. Continuing aspirin therapy during percutaneous nephrolithotomy: unsafe or under-utilized? J Endourol. 2014;28:1399-403.
Otto BJ, Terry RS, Lutfi FG, Syed JS, Hamann HC, Gupta M, et al. The Effect of Continued Low Dose Aspirin Therapy in Patients Undergoing Percutaneous Nephrolithotomy. J Urol. 2018;199:748-53.
Wang WG, Wang CY, Jia K, Lu ZP. The effect of hemorrhage and safety of perioperative aspirin administration on minimal percutaneous nephrostolithotomy. International Journal of Urology and Nephrology. 2019:833-6.
Leyh-Bannurah SR, Hansen J, Isbarn H, Steuber T, Tennstedt P, Michl U, et al. Open and robot-assisted radical retropubic prostatectomy in men receiving ongoing low-dose aspirin medication: revisiting an old paradigm? BJU Int. 2014;114:396-403.
Maan Z, Cutting CW, Patel U, Kerry S, Pietrzak P, Perry MJ, et al. Morbidity of transrectal ultrasonography-guided prostate biopsies in patients after the continued use of low-dose aspirin. BJU Int. 2003;91:798-800.
Giannarini G, Mogorovich A, Valent F, Morelli G, De Maria M, Manassero F, et al. Continuing or discontinuing low-dose aspirin before transrectal prostate biopsy: results of a prospective randomized trial. Urology. 2007;70:501-5.
Mackinnon B, Fraser E, Simpson K, Fox JG, Geddes C. Is it necessary to stop antiplatelet agents before a native renal biopsy? Nephrol Dial Transplant. 2008;23:3566-70.
Nayak-Rao S. Percutaneous native kidney biopsy in patients receiving antiplatelet agents- is it necessary to stop them routinely? Indian J Nephrol. 2015;25:129-32.
Eng M, Brock G, Li X, Chen Y, Ravindra KV, Buell JF, et al. Perioperative anticoagulation and antiplatelet therapy in renal transplant: is there an increase in bleeding complication? Clin Transplant. 2011;25:292-6.
Naspro R, Lerner LB, Rossini R, Manica M, Woo HH, Calopedos RJ, et al. Perioperative antithrombotic therapy in patients undergoing endoscopic urologic surgery: where do we stand with current literature? Minerva Urol Nefrol. 2018;70:126-36.
El-Nahas AR, Shokeir AA, El-Assmy AM, Mohsen T, Shoma AM, Eraky I, et al. Post-percutaneous nephrolithotomy extensive hemorrhage: a study of risk factors. J Urol. 2007;177:576-9.
Ramon de Fata F, Perez D, Resel-Folkersma L, Galan JA, Serrano A, Servera A, et al. Analysis of the factors affecting blood loss in percutaneous nephrolithotomy: a registry of the Spanish Association of Urology in the supine position. Actas Urol Esp. 2013;37:527-32.
Kukreja R, Desai M, Patel S, Bapat S, Desai M. Factors affecting blood loss during percutaneous nephrolithotomy: prospective study. J Endourol. 2004;18:715-22.
Mishra DK, Bhatt S, Palaniappan S, Reddy TVK, Rajenthiran V, Sreeranga YL, et al. Mini versus ultra-mini percutaneous nephrolithotomy in a paediatric population. Asian J Urol. 2022;9:75-80.
Haghighi R, Zeraati H, Ghorban Zade M. Ultra-mini-percutaneous nephrolithotomy (PCNL) versus standard PCNL: A randomised clinical trial. Arab J Urol. 2017;15:294-8.
Vollstedt A, Bustos NH, Eisner B, Dagrosa L, Pais V. Is it safe to continue anti-platelet and anticoagulation therapy in patients undergoing percutaneous nephrolithotomy (PCNL)? A nested case control study. Journal of Urology. 2016;195:e506.
Johnson E, Bechis S, Deshmukh S, Barboglio-Romo P, Eisner B, Pais Jr V. Impact of perioperative anticoagulation on incidence of bleeding complications in patients undergoing percutaneous nephrolithotomy. Journal of Urology. 2013;189:e632.
Collet JP, Montalescot G, Blanchet B, Tanguy ML, Golmard JL, Choussat R, et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation. 2004;110:2361-7.
Biondi-Zoccai GG, Lotrionte M, Agostoni P, Abbate A, Fusaro M, Burzotta F, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J. 2006;27:2667-74.
Oscarsson A, Gupta A, Fredrikson M, Jarhult J, Nystrom M, Pettersson E, et al. To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial. Br J Anaesth. 2010;104:305-12.
- Abstract Viewed: 0 times
- 7170/pdf Downloaded: 0 times